2026-10-24T15:30:16Zhttps://gumushane-rdlopen.rawdatalibrary.net/oai/request

oai:gumushane-rdlopen.rawdatalibrary.net:gumushane/146492026-10-23T21:03:37Zopenairedrivercom_gumushane_10000col_gumushane_10001

COVID-19 vaccine and immune responseHintistan, SevilayDemirağ, HaticeCOVID-19immune responsevaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2; βCoV), the causative agent of coronavirus disease 2019 (COVID-19), causes severe lower respiratory tract infections and acute respiratory failure syndrome (ARDS). Deaths due to the ongoing COVID-19 pandemic for more than a year are still seen worldwide. Therefore, vaccine trials have gained importance. The discovery of the genome and protein structure of SARS-CoV-2 in a short time allowed the development of nucleic acid-based vaccines (mRNA and DNA vaccines), vector vaccines, inactivated virus vaccines, protein-based vaccines, virus-like particle vaccines, and live attenuated virus vaccines. Many companies, universities, and institutes around the world continue to develop effective vaccines against SARS-CoV-2. In this review, the structural features, classification, genome, and intracellular entry of SARS-CoV-2 coronaviruses, stimulation of the immune system and immunity, COVID-19 vaccine types, and the latest status of clinical trials of these vaccines have been reviewed.Open Exploration Publishing Inc2021Review Articlehttps://rdlopen.rawdatalibrary.net/r/gumushane/14649https://doi.org/10.37349/ei.2021.000232768-6655enExploration of Immunologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/reviewhttps://gumushane-rdlopen.rawdatalibrary.net/tr/items/gumushane/14649